~~<i id='5B26628C19'><strike id='5B26628C19'><tt id='5B26628C19'><pre id='5B26628C19'></pre></tt></strike></i>~~

Home» leisure time» explore

explore

author：explore 2025-09-29 06:11:25 Page View：16582

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： US judge blocks portions of new Florida elections law
Next article： Psychedelics group wrestles with new pharma identity

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

WallStreetJournalreporterEvanGershkovichstandsinaglasscageinacourtroomattheMoscowCityCourtinMoscow,R

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Judge agrees to delay next hearing in Trump classified documents case

1:01FormerPresidentandRepublicanpresidentialcandidateDonaldTrumppreparestodeliverremarksataNevadaRep